{"id":11248,"date":"2019-07-26T00:00:00","date_gmt":"2019-07-26T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/darzalex-approuve-en-saskatchewan\/"},"modified":"2025-08-19T08:28:21","modified_gmt":"2025-08-19T13:28:21","slug":"darzalex-approuve-en-saskatchewan","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/","title":{"rendered":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN!"},"content":{"rendered":"<p>Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats.<\/p>\n<p><a href=\"http:\/\/www.saskcancer.ca\/Formulary%2007-2019\" target=\"_blank\" rel=\"noopener\">Consulter la circulaire <\/a>(en anglais)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11248","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN! | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2019-07-26T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:21+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN! | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#blogposting\",\"name\":\"DARZALEX APPROUV\\u00c9 EN SASKATCHEWAN! | My\\u00e9lome Canada\",\"headline\":\"DARZALEX APPROUV\\u00c9 EN SASKATCHEWAN!\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2019-07-26T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:21-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#listItem\",\"name\":\"DARZALEX APPROUV\\u00c9 EN SASKATCHEWAN!\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#listItem\",\"position\":4,\"name\":\"DARZALEX APPROUV\\u00c9 EN SASKATCHEWAN!\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/\",\"name\":\"DARZALEX APPROUV\\u00c9 EN SASKATCHEWAN! | My\\u00e9lome Canada\",\"description\":\"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \\u00e9t\\u00e9 approuv\\u00e9 en association avec le l\\u00e9nalidomide et la dexam\\u00e9thasone (DRd) ou avec le bortezomib et la dexam\\u00e9thasone (DVd) pour le traitement des patients atteints d\\u2019un my\\u00e9lome multiple ayant re\\u00e7u au moins un traitement pr\\u00e9c\\u00e9dent et ayant de bons r\\u00e9sultats. Consulter la circulaire (en anglais)\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2019\\\/07\\\/26\\\/darzalex-approuve-en-saskatchewan\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2019-07-26T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:21-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN! | My\u00e9lome Canada","description":"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)","canonical_url":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#blogposting","name":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN! | My\u00e9lome Canada","headline":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN!","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2019-07-26T00:00:00-05:00","dateModified":"2025-08-19T08:28:21-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#listItem","name":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN!"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#listItem","position":4,"name":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN!","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/","name":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN! | My\u00e9lome Canada","description":"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2019-07-26T00:00:00-05:00","dateModified":"2025-08-19T08:28:21-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN! | My\u00e9lome Canada","og:description":"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)","og:url":"https:\/\/myeloma.ca\/fr\/2019\/07\/26\/darzalex-approuve-en-saskatchewan\/","article:published_time":"2019-07-26T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:21+00:00","twitter:card":"summary_large_image","twitter:title":"DARZALEX APPROUV\u00c9 EN SASKATCHEWAN! | My\u00e9lome Canada","twitter:description":"Depuis le 15 juillet, en Saskatchewan, Darzalex (daratumumab) a \u00e9t\u00e9 approuv\u00e9 en association avec le l\u00e9nalidomide et la dexam\u00e9thasone (DRd) ou avec le bortezomib et la dexam\u00e9thasone (DVd) pour le traitement des patients atteints d\u2019un my\u00e9lome multiple ayant re\u00e7u au moins un traitement pr\u00e9c\u00e9dent et ayant de bons r\u00e9sultats. Consulter la circulaire (en anglais)"},"aioseo_meta_data":{"post_id":"11248","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 17:04:47","updated":"2026-04-30 07:29:56","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11248"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11248\/revisions"}],"predecessor-version":[{"id":31326,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11248\/revisions\/31326"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}